Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
jeudi, novembre 19
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
BioHarvest Sciences Inc
BHST
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$1.23
0.01
0.82%
À la clôture: Nov 18, 4:00 PM EST
$1.22
-0.01
-0.81%
Après les heures: 7:36 AM EST
Get Report
Aperçu
Actualités
Graphiques
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Comparer
Rapport sur les stocks
BioHarvest Sciences Financials
BioHarvest Sciences (BHST) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Conference call: BioHarvest Sciences Lowers FY2026 Sales Guidance from $37.000M-$40.000M to $32.000M-$33.500M vs $37.461M Est
BioHarvest Sciences (NASDAQ:BHST) lowers FY2026 sales outlook from $37.000 million-$40.000 million to $32.000 million-$33.500 million vs $37.461 million estimate.
Benzinga Newsdesk
PRO
BioHarvest Sciences Inc. - Common Stock Q3 EPS $(0.15) Misses $(0.14) Estimate, Sales $7.867M Miss $9.371M Estimate
BioHarvest Sciences Inc. - Common Stock (NASDAQ:BHST) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.14) by 7.14 percent. This is a 7.14 percent decrease over losses of
Benzinga Newsdesk
PRO
Conference Call: BioHarvest Sciences Lowers FY2026 Sales Guidance from $42.000M-$48.000M to $37.000M-$40.000M vs $42.914M Est
BioHarvest Sciences (NASDAQ:BHST) lowers FY2026 sales outlook from $42.000 million-$48.000 million to $37.000 million-$40.000 million vs $42.914 million estimate.
Benzinga Newsdesk
PRO
BioHarvest Sciences Revises FY26 CDMO Revenue Guidance to $4M-$5M from $4M-$6M; VINIA D2C Revenue Guidance to $33M-$35M from $38M-$42M
BioHarvest Sciences (NASDAQ:BHST) stated that full-year 2026 revenue guidance for its CDMO business has been narrowed to $4 million-$5 million, from $4 million-$6 million previously, while revenue guidance for the VINIA
Benzinga Newsdesk
PRO
BioHarvest Sciences Inc. - Common Stock Q2 EPS $(0.17) Misses $(0.12) Estimate, Sales $8.837M Miss $9.537M Estimate
Benzinga Newsdesk
PRO
BioHarvest Sciences Affirms FY2026 Sales Guidance of $42.000M-$48.000M vs $44.721M Est
BioHarvest Sciences (NASDAQ:BHST) affirms FY2026 sales outlook from $42.000 million-$48.000 million to $42.000 million-$48.000 million vs $44.721 million estimate.
Benzinga Newsdesk
Résultats:
Les résultats Q3 2026 ont été publiés le jeu. nov. 12th, avant l'ouverture du marché
Conférence téléphonique:
La conférence téléphonique la plus récente a commencé à 8:00 AM, il y a 6 jours
Cliquez pour voir la webdiffusion